“CAR T cell therapy” Science-Research, December 2021, Week 2 — summary from ClinicalTrials.gov and PubMed

ClinicalTrials.gov — summary generated by Brevi Assistant

Patients eligible to obtain CAR T-cell therapy for FDA-approved indicators in hematological malignancies will be registered in this research on the day of CAR T-cell infusion. The research study’s additional endpoint is to analyze the response rate of siltuximab in the resolution of ICANS, the security of siltuximab, and the overall response rate of CAR T-cell therapy. In this research study, investigators will enroll 10 topics with relapsed/refractory cHL that have previously been treated with anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have proof of development. Initial data from topics treated with anti-PD-1 therapy after progression following CD30 CAR-T cell therapy has suggested remarkably durable professional responses to anti-PD-1 therapy. Human Leukocyte Antigen is a protein on the exterior of cells that permits the immune system to recognize it’s own cells as normal and leave them alone or react if infected with a virus or bacteria, or a lump cell. The gathered T cells will be saved for patients that are most likely to take advantage of CAR T-cell therapy during their illness care. This is an open label, multi-center, Phase 1b scientific test to review the safety and effectiveness of autologous claudin18. 2 chimeric antigen receptor T-cell therapy in patients with advanced stomach or pancreatic adenocarcinoma. Adhering to approval, patients must have growth tissue assessed by CLDN18. 2 IHC assay. To establish the optimum tolerated dose of internal, point of treatment manufactured IC19/1563 in patients with relapsed/refractory B cell malignancies. Define the in vivo cellular kinetics account of CAR19 transgene and CD3+CAR+ cells into blood. Hepatocellular cancer is the 5th most common cancer in the world and the second leading source of cancer-associated death with an ordinary life span of 6–9 months. We intend to examine the function of GPC3 targeted chimeric antigen receptor -T cells in advanced GPC3 expressing HCC.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

  • https://clinicaltrials.gov/ct2/show/NCT04975555 — A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies.
  • https://clinicaltrials.gov/ct2/show/NCT04134325 — A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed Refractory Classical Hodgkin Lymphoma.
  • https://clinicaltrials.gov/ct2/show/NCT04981119 — An Observational Study Obtaining Solid Tumor Tissue From Subjects With Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing.
  • https://clinicaltrials.gov/ct2/show/NCT04404595 — Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18. 2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma.
  • https://clinicaltrials.gov/ct2/show/NCT04892277 — Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed Refractory B Cell Malignancies.
  • https://clinicaltrials.gov/ct2/show/NCT05003895 — Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC).

PubMed — summary generated by Brevi Assistant

Idecabtagene vicleucel, a novel chimeric antigen receptor T-cell therapy targeting B-cell growth antigen, has recently acquired authorization by the US FDA for fallen back and refractory numerous myeloma after multicenter tests have shown unprecedented results in this difficult-to-treat subgroup of patients. As the first CAR T-cell item authorized for myeloma, ide-cel is positioned to end up being a practice-changing therapy choice. Chimeric antigen receptor T-cell therapy can generate resilient remissions of relapsed/refractory B-acute lymphoblastic leukemia. We recognized kids and young adults with relapsed/refractory CD19+ ALL/lymphoblastic lymphoma treated in 5 CD19-directed CAR T-cell professional trials or with commercial tisagenlecleucel from April 2012 to April 2019. The fallen back and refractory acute myeloid leukemia patients obtaining traditional chemotherapies have an inadequate survival rate. Most CAR-Ts targeting the prospect proteins on AML cells induce hematopoietic cell suppression. Chimeric Antigen Receptor T cell therapy is a novel adoptive immunotherapy that is changing the therapy of strong tumors and haematological malignancies. Preserving a patient’s dietary condition and executing nourishment support interventions have been shown to improve particular patient results in basic anti-cancer therapies; nonetheless, support for nourishment support treatments in CAR T cell therapy is lacking. Chimeric antigen receptor T-cell therapy integrates antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. Our algorithm forecasted TAAs being presently discovered preclinically and in clinical CAR-T AML therapy tests, in addition to novel TAAs in pediatric megakaryoblastic AML.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

Brief Info about Brevi Assistant

The Brevi assistant is a novel way to automatically summarize, assemble, and consolidate multiple text documents, research papers, articles, publications, reports, reviews, feedback, etc., into one compact abstractive form.

At Brevi Assistant, we integrated the most popular open-source databases to empower Researchers, Teachers, and Students to find relevant Contents/Abstracts and to always be up to date about their fields of interest.

Also, users can automate the topics and sources of interest to receive weekly or monthly summaries.

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store